Oncternal Theraputics, Inc is a clinical-stage oncology company developing first-in-class and novel therapies for cancers. The company’s pipeline includes two clinical-stage products. Cirmtumzab and TK216 which are being developed for various tumor types, including some of the most devastating and underserved forms of cancer. Cirmtuzumab is a humanized IgG1 monoclonal antibody designed and developed to bind with high affinity to a biologically important epitope on the extracellular domain of Receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1). ROR1 is a type 1 transmembrane protein expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells, but does not recognize normal human tissues. Cirmtuzumab is currently being tested in a phase 1 trial for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults. TK216 is a small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins in a variety of tumor types, stopping cancer cell growth and tumor formation. TK217 is currently in Phase One study for patients with relapsed or refractory Ewing Sarcoma.

Immusoft, Inc is a breakthrough autologous cell therapy platform for treating a variety of human diseases through a proprietary Immune System Programming (ISP™) technology. ISP™ technology can effectively re-program a patient’s own cells to become miniature drug factories in the body. The technology was designed to address current challenges faced with the production and delivery of conventional protein therapeutic drugs (biologics). The ISP™ platform enables safe insertion of genes encoding the correct human homolog of a missing or defective protein(s) into a patient’s immune cells using the Sleeping Beauty (SB) transposon system, a non-viral vector. Immusoft has been granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I). MPS I is a rare, childhood genetic disease that affects the body’s ability to produce an essential enzyme to break down long sugar chains inside cells. When the sugar chains can’t be broken down and disposed of, they accumulate in the body’s cells, which causes progressive damage. Immusoft was the winner of the 2018 “Most Promising Company Award” from the Precision Medicine World Conference, held in Silicon Valley. The award recognizes companies with especially promising and innovative health care diagnostic, therapeutic and technological solutions.

RetroSense Therapeutics, LLC (Acquired by Allergan in 2016 for up to $550MM) is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness. RST-001 is a first-in-class gene therapy application of optogenetics, a therapeutic approach that confers light sensitivity to cells that were not previously, or natively, light sensitive by applying optogenetics to retinas in which rod and cone photoreceptors have degenerated. In 2014, RST-001 received an Orphan Drug Designation by the US FDA for the treatment of Retinitis Pigmentosa.

VelosBio, LLC was spun out from Oncternal Theraputics in 2017 to provide a platform for additional investment into and the specific research associated with Oncternal Theraputics’ ROHR1 antibodies portfolio for use in antibody drug congregates. Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. These novel, targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

Iridium, Inc (Formerly Dodo OmniData) was established in 2016 to develop a commercially-attractive, DNA-based data storage solution. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridium is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density.

Pyramid Home Health Services (Acquired by Jordan Health Services in 2018 for an undisclosed amount) was founded in 1972 and provides a full array of (HCBS) home and community based health services, including long-term-care, pharmacy, home health and hospice services. More than 4,000 individuals in 110- Missouri counties receive some type of home delivered health service from a Pyramid Home Health Services company daily.

Rocio Romero, LLC is the designer, manufacturer and builder of a line of simple, modern, green single family kit homes known as the LV Home series. Rocio Romero was founded in 2000 and has completed to date several hundred homes across the continental United States, Canada, South America, and Europe.  In addition to its commercial success, Rocio Romeo has been the subject of numerous publications including the New Yorker, Inc., Wall Street Journal, New York Times, Dwell as well as been exhibited in many museums including at the Walker Art Center, The Museum of Contemporary Art in Los Angeles, the Vancouver Art Gallery, and the Triennale di Milano.

Intentional Housing, LLC is engaged in consulting, development and syndication of publically financed affordable housing paired with 1915 waiver and Medicaid state-plan services. The company’s merged housing, technology and services model is designed to positively impact at-risk populations’ social determinants of health. The company’s projects are designed to reduce Medicaid and Medicare spending for state and federal government and managed care organizations. By partnering with Intentional Housing, the ROI to the state and federal government on an allocation of LIHTC and NMTC is substantially boosted as a result of its funding project specifically designed to avoid exacerbation of chronic illness, hospitalization, and premature institutional placement. Pending projects include communities for young adults with developmental disabilities that provide on-site life and employment skills training and supported work opportunities and senior housing paired with artificial intelligence (AI) enabled sensor technology, adult daycare and Home and Community Based waiver services designed to predict and mitigate fall risk, CHF exacerbation, UTI and other costly and adverse health events. The principals of Intentional Housing, LLC have facilitated in excess of $1 billion of affordable housing development and HCBS delivery nationally since 2008.

FSM Funds I & II invest in emerging growth companies in a variety of industries. The current portfolio includes Lions Choice, a QSR chain founded in 1964 and specializing in premium roast beef sandwiches. Lions Choice currently has 23- locations in St. Louis Missouri. Native Foods, also in the QSR space, is one of the nation’s premier fast casual vegan food chains and operates restaurants in California, Colorado, Oregon and Illinois. Additional FSM Funds’ investments include Hardin Industries, which produces high quality weather proofed and sound attenuated generator set enclosures and UL142 listed base fuel tanks and trailers and TPS Operations, a full service print production company.